SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Surrozen, Inc./DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$23.84+0.40 (+1.71%)

Close on Oct 19, 2026

Market cap: $551.80M
P/E (TTM): –
Dividend yield: –

Surrozen, Inc./DE cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31
Depreciation & Amortization	0.05	0.07	0.05	0.06	0.14	0.29	0.32	0.34	0.45	0.48	0.50	0.48	0.48	0.47	0.47	0.53	0.54	0.53	0.49	0.51	0.47
Stock-Based Compensation	2.89	2.11	1.00	1.01	0.99	0.83	0.90	1.04	1.17	0.91	1.16	1.13	1.55	1.08	0.98	0.92	0.69	0.62	0.53	0.48	0.19
Deferred Income Taxes	0	0	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	0	-5.00	2.04	0	0	0	10	-10	0	–	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Payable	0.18	0.16	-0.09	0.18	0.05	0.00	0.02	0.10	0.24	0.10	0.02	-0.49	0.33	-0.09	-0.52	-1.76	0.73	0.77	-1.07	0.43	0.53
Operating Cash Flow	-7.42	-12	-5.81	-9.04	-6.11	-9.28	3.48	-6.75	-7.31	-10	-8.75	-14	-0.21	-14	-11	-18	-12	-14	-13	-10	-9.34
Capital Expenditures	-0.02	-0.12	-0.06	-0.02	-0.02	-0.03	-0.02	0	0	0	-0.08	-0.32	-0.15	-0.15	-0.02	-0.41	-0.32	-0.54	-0.06	-0.34	-0.46
Purchase of Investments	–	–	–	–	–	–	0	0	0	-9.35	-11	-7.86	-8.71	-21	0	0	-17	-73	0.00	-1.10	-14
Sale & Maturity of Investments	–	–	–	–	–	–	0	0	9.50	17	28	26	11	44	14	0	1.10	4.40	–	–	0
Investing Cash Flow	-0.02	-0.12	-0.06	-0.02	-0.02	-0.03	-0.02	0	9.50	7.65	17	17	1.91	23	14	-0.41	-17	-68	8.64	-1.44	-15
Stock Issued	0	0	3.50	0	-5.19	76	0	0.00	0	0	–	–	0	–	–	–	0.13	–	–	–	0
Financing Cash Flow	2.51	30	14	0.01	-5.12	76	0.09	0.00	0.14	-0.01	0.19	-0.04	-2.55	-0.01	0.00	0	0.16	125	-0.31	0.20	0.06
Net Change in Cash	-4.92	18	7.91	-9.06	-11	67	3.55	-6.75	2.33	-2.50	8.69	3.12	-0.84	8.67	2.56	-19	-28	42	-4.55	-12	-24
Free Cash Flow	-7.43	-13	-5.87	-9.06	-6.13	-9.31	3.46	-6.75	-7.31	-10	-8.83	-14	-0.35	-14	-11	-19	-12	-15	-13	-11	-9.80

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -385.3%
Net margin: -2885.3%
Return on equity, FY2025: 231.4%

Financial strength

Current ratio: 12.14
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1132.4%

Valuation

P/E ratio: –
Price to sales: 47.94
Price to book: –
Dividend yield: –